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Abstract
Background: Butylidenephthalide (Bdph), a main constituent of Ligusticum chuanxiong Hort., was reported to have
selective antianginal effect without changing blood pressure in conscious rat. Recently, we have observed that Bdph
antagonized cromakalim, an ATP-dependent K+ channel opener, in guinea-pig trachea. Thus, we were interested in
investigating whether Bdph at the dose without changing blood pressure antagonized cromakalim-induced systolic
pressure reduction in conscious rats.
Methods: Systolic arterial pressures of conscious rats were determined by using the indirect tail-cuff method.
Results: Bdph (30 mg/kg, i.p.) did not affect baseline systolic pressure in conscious normotensive and spontaneous
hypertensive rats. Bdph (30 mg/kg, i.p.) also did not affect log dose–response curves of prazosin, clonidine and Bay K
8644, a Ca2+ channel activator, in normotensive rats. However, Bdph (30 mg/kg, i.p.) similar to 4-aminopyridine (4-AP,
0.4 mg/kg, i.p.), a K+ channel blocker, non-parallelly but surmountably, and partially similar to glibenclamide (GBC,
10 mg/kg, i.v.), an ATP-sensitive K+ channel blocker, surmountably but not parallelly rightward shifted the log dose-
systolic pressure reduction curve of cromakalim, an ATP-sensitive K+ channel opener, in normotensive rats, respectively.
Discussion: The antagonistic effect of Bdph against cromakalim was similar to that of 4-AP, a K+ channel blocker of Kv1
family, and partially similar to that of GBC, an ATP-sensitive K+ channel blocker. Thus, Bdph may be a kind of K+ channel
blockers, which have been reviewed to have a potential clinical use for Alzheimer disease. Indeed, Bdph has also been
reported to reverse the deficits of inhibitory avoidance performance and improve memory in rats. Recently, 4-AP was
reported to treat Episodic ataxia type 2 (EA2) which is a form of hereditary neurological disorder. Consistently, Bdph was
recently reported to have antihyperglycemic activity in mice, since GBC is a powerful oral hypoglycemic drug.
Conclusions: Bdph similar to 4-AP and partially similar to GBC may block Kv1 family and ATP-sensitive K
+ channels in
conscious normotensive rats.
Keywords: 4-Aminopiridine, ATP-sensitive K+ channels, Kv1 family of K
+ channels, Butylidenephthalide, Conscious
normotensive rats, Cromakalim
Background
The rhizome of Ligusticum chuanxiong Hort. (previously
named as L. wallichii Franch., Umbelliferae) have been
used by the Chinese for several thousand years. In an-
cient medical literature, such as Shen-Nung-Pen-Tsao-
Ching, the rhizome of L. chuanxiong Hort. was delin-
eated to prevent and restore stroke-induced dyskinesia.
From the neutral oil of the rhizome we isolated and
purified three antispasmodics, butylidenephthalide
(Bdph), ligustilide and butylphthalide [1, 2]. Bdph was
reported to inhibit cyclooxygenase and to have anti-
platelet effects [3]. Shimotsu-to, a prescription of trad-
itional Chinese medicine, had antiproliferative effects in
primary cultures of mouse aorta smooth muscle cells
[4], mainly due to the effect of Bdph [5]. Both anti-
platelet and antiproliferative effects of Bdph may benefit
to prevent ischemic stroke. To recover from stroke-
induced dyskinesia the damaged nervous tissue needs to
* Correspondence: wc_ko@tmu.edu.tw
2Department of Pharmacology, College of Medicine, Taipei Medical
University, 250 Wu-Hsing St., Taipei 110, Taiwan
Full list of author information is available at the end of the article
© 2015 Shih et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shih et al. BMC Complementary and Alternative Medicine  (2015) 15:344 
DOI 10.1186/s12906-015-0877-z
repair by itself. The vasodilating effects of Bdph [6–8]
improve the circulation and may partially benefit this
restoration. Recently, Bdph was reported to provide neu-
roprotection by reducing the release of various proin-
flammatory molecules from activated microglia [9],
Bdph was also reported to maintain stem cell pluripo-
tency by activating the Jak2/Stat3 pathway and to in-
crease the efficiency of induced pluripotent stem cells
generation [10]. These results highlight the ability for
these crude drugs to aid in the recovery from dyskinesia.
Interestingly, Bdph was also reported to inhibit growth
of hepatocellular carcinoma [11], colon cancer [12], and
prostate cancer [13] with a high therapeutic ratio [14].
Bdph was reported to inhibit Ca2+ influx and cause re-
laxation in guinea-pig ileum [15], rat aortic ring [8] and
rabbit aortic strip [6]. Bdph was also reported to increase
flow in isolated guinea-pig heart [16] and rabbit ear [6].
However, Bdph was reported to have selective antiangi-
nal effect without changing blood pressure in conscious
rat [7]. The effect of Bdph on blood pressure is obviously
different from that of nitroglycerin, an antianginal drug,
which occasionally causes hypotension and vertigo. Re-
cently, we have reported that Bdph antagonized croma-
kalim, an ATP-sensitive K+ channel opener, in guinea-
ping trachea [17]. Thus, we were interested in investigat-
ing whether Bdph at the dose without changing blood
pressure antagonized cromakalim in conscious rat. In
the preliminary test, an intraperitoneal (i.p.) injection of
Bdph at 30 mg/kg did not influence the systolic pressure
of conscious normotensive and spontaneous hyperten-
sive rats. However, Bdph at 60 mg/kg (i.p.) induced sys-
tolic pressure reduction itself, and at 15 mg/kg (i.p.) did
not antagonize the effect of cromakalim.
Methods
Drugs and animals
Bdph was synthesized according to the previously de-
scribed method [18]. The compound was light yellow
oily substance. The structure is shown as Fig. 1. 4-
Aminopyridine (4-AP, a K+ channel blocker) and gliben-
clamide (GBC, an ATP-sensitive K+ channel blocker
[19]) were purchased from Sigma-Aldrich, St. Louis,
MO, U.S.A. Prazosin (an α1-adrenoceptor antagonist),
clonidine (an α2-adrenoceptor agonist), Bay K 8644 (a
Ca2+ channel activator), and cromakalim (BRL 34915, an
ATP-sensitive K+ channel opener), were gifts from Pfizer,
U.S.A., Boehringer Sohn, Germany, Bayer Leverkusen,
Germany, and SmithKline Beecham Pharmaceutical,
U.K., respectively. Bdph and prazosin were dissolved in
95 % ethyl alcohol. When used, Bdph was diluted to 3 %
in saline. Bay K 8644 and nifedipine were dissolved in a
mixture of 2 % ethyl alcohol, 5 % polyethylene glycol
400 (PEG 400) and 1 % Tween 80 in saline. Cromakalim
was dissolved in a mixture of PGE 400: saline (1:1, w/v).
GBC was dissolved in 1 M NaOH first and then diluted
in 5 % dextrose (1: 39). Clonidine and 4-AP were dis-
solved in saline.
Male normotensive (Wistar) and spontaneous hyper-
tensive (SHR) rats, weighting 200 ~ 300 g, were pur-
chased from the Animal Center of the Ministry of
Science and Technology, Taipei, Taiwan. The animals
were housed in ordinary cages at 22 ± 1 °C with a hu-
midity of 50 ~ 60 % under a constant 12/12-h light/dark
cycle and provided with food and water ad libitum.
Under a protocol approved by the Animal Care and Use
Committee of Taipei Medical University, the following
in vivo experiments were performed.
Determination of systolic arterial pressure
After training for a week, these conscious rats were indi-
vidually put into acrylic restraining cage on a warm plate
(38 ~ 40 °C), and kept their tails warm (35 ~ 37 °C). The
systolic arterial pressure of rat was determined by using
the indirect tail-cuff method [20]. Briefly, when the cuff
pressure was elevated to cut off the blood flow by inflat-
ing a bulb, no pulse was detected by a pneumatic sensor
(International Biomedical Inc., Houston, TX, U.S.A.),
which was put along the tail artery of rat. When cuff
pressure was reduced (−20 mmHg/s) to allow the blood
flow, the pulse was detected by the sensor. As the begin-
ning of pulse appeared the cuff pressure was the systolic
pressure of rat.
Effects of Bdph on systolic pressure in normotensive and
spontaneous hypertensive rats
Systolic pressures of rats were determined in an interval
of 15 min. Four baseline values were taken before Bdph
(30 mg/kg, i.p.) or its vehicle (1 ml/kg, i.p., control)
Fig. 1 The chemical structure of butylidenephthalide (Bdph, mol.
wt. 188.23)
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injection. After injection (0 min), both rats were con-
tinuously determined each 15 min for 1 h. After 1 h,
however, normotensive rats were continuously deter-
mined each hr for another 2 h.
Effect of Bdph on prazosin- or clonidine-induced systolic
pressure reduction in normotensive rats
Systolic pressures of rats were determined in an interval
of 15 min, with the exception that an additional deter-
mination was performed at 7.5 min after intravenous
(i.v.) injection of clonidine to avoid losing effective
values. Baseline values were taken before injection of
Bdph (30 mg/kg, i.p.) or its vehicle. Thirty min after in-
jection, prazosin (0.1 ~ 3 mg/kg, i.p.) or clonidine (0.003
~ 0.03 mg/kg, i.v.) was additionally injected. In 1 h after
injection of prazosin or clonidine, the maximal systolic
pressure reduction was collected, and the log dose–re-
sponse curve was constructed.
Effect of Bdph on Bay K 8644-induced systolic pressure
elevation in normotensive rats
Systolic pressures of rats were determined in an interval
of 15 min, with the exception that an additional deter-
mination was performed at 7.5 min after intravenous
(i.v.) injection of Bay K 8644 to avoid losing effective
values. Two baseline values were taken before injection
of Bdph (30 mg/kg, i.p.), nifedipine (1 mg/kg, i.v.), a ref-
erence drug, or their vehicles. Thirty min after injection
of Bdph or 5 min after injection of nifedipine, Bay K
8644 (0.03 ~ 0.6 mg/kg, i.v.) was additionally injected. In
1 h after injection of Bay K 8644, the maximal hyperten-
sive response was collected, and the log dose–response
curve was constructed.
Effect of Bdph on the responses of cromakalim in
normotensive rats
Systolic pressures of rats were determined in an interval
of 15 min, with the exception that an additional deter-
mination was performed at 7.5 min after i.v. injection of
cromakalim to avoid losing effective values. Two base-
line values were taken before injection of Bdph (30 mg/
kg, i.p.), 4-Ap (0.4 mg/kg, i.p.), GBC (10 mg/kg, i.v.), or
their vehicles. 4-AP and GBC were used as reference
drugs. Thirty min after injection of Bdph, 4-AP or GBC,
cromakalim was additionally injected (i.v.) at doses from
0.075 to 1.2 mg/kg for Bdph-, to 0.6 mg/kg for 4-AP-,
and to 2.4 mg/kg for GBC-treated rats. In 1 h after injec-
tion of cromakalim, the maximal systolic pressure reduc-
tion was collected, and the log dose–response curve was
constructed.
Statistical analysis
The values of maximal response (Emax) and slope (S) of
these log dose–response curves were generated from the
softward of SigmaPlot 10. The effective dose at 50 % of
the maximal response (ED50) value was calculated from
linear regression. All values were expressed as mean ±
SEM, n was the number of experiment. Differences
among three values were statistically calculated by one-
way analysis of variance (ANOVA), and then determined
by Dunnett’s test. The difference between two values
was determined by Student's paired or unpaired t-test.
Differences of P < 0.05 were considered statistically
significant.
Results
No effect of Bdph on systolic pressure in normotensive or
spontaneous hypertensive rats
The mean values of baseline systolic pressure of normo-
tensive and spontaneous hypertensive rats were 112 ±
4 mmHg (n = 9) and 160 ± 2 mmHg (n = 8), respectively.
Bdph (30 mg/kg, i.p.) had no effects on systolic pressure
in normotensive and spontaneous hypertensive rats, be-
tween before and after injection or between test and
control (Fig. 2a, b).
No effects of Bdph on prazosin- and clonidine-induced
systolic pressure reduction in normotensive rats
Bdph (30 mg/kg, i.p.) did not significantly affect the log
dose–response curves of prazosin and clonidine when
compared to their controls (data not shown).
No effect of Bdph on Bay K 8644-induced hypertensive
response in normotensive rats
Bdph (30 mg/kg, i.p.) did not significantly affect the log
dose–response curve of Bay K 8644, when compared to
its control (data not shown).
However, nifedipine (1 mg/kg, i.v.) downward shifted
the log dose–response curve of Bay K 8644, and signifi-
cantly reduced the change of systolic pressure at each
dose of Bay K 8644 when compared to its control (data
not shown).
Effects of Bdph and other K+ channel blockers on
cromakalim-induced systolic pressure reduction in
normotensive rats
The pretreatment of Bdph (30 mg/kg, i.p.) or 4-AP
(0.4 mg/kg, i.p.) did not influence the baseline systolic
pressure in normotensive rats. Both treatments signifi-
cantly antagonized the cromakalim-induced decrease of
systolic pressure (Fig. 3a, b). The antagonistic effect of
Bdph lasted for 45 min, but that of 4-AP did only for
15 min (Fig. 3a, b). The pretreatment of GBC (10 mg/kg,
i.v.) also did not influence baseline systolic pressure, but
significantly antagonized cromakalim-induced decrease of
systolic pressure (Fig. 3c). The antagonistic effect of GBC
lasted for 45 min.
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Bdph (30 mg/kg, i.p.) and 4-AP (0.4 mg/kg, i.p.) non-
parallelly but surmountably rightward shifted the log-dose
response curve of cromakalim for change in systolic pres-
sure (Fig. 4a, b). Both slopes of curves were significantly
greater than their controls without influencing their Emax
values, and significantly increased their ED50 values, re-
spectively (Table 1). However, GBC (10 mg/kg, i.v.) paral-
lelly and surmountably (competitively) rightward shifted
the log-dose response curve of cromakalim for change in
systolic pressure (Fig. 4c), as the slope and Emax values
were not significantly different from its control (vehicle).
GBC also significantly increased the ED50 value (Table 1).
Discussion
Bdph at the dose of 30 mg/kg (i.p.) did not influence sys-
tolic pressure in conscious normotensive or spontaneous
hypertensive rats, although Bdph at the dose was reported
to reduce the systolic pressure in anesthetized renal hyper-
tensive rats [6], suggesting that conscious rats keep intact
reflex to offset the effect of Bdph on systolic pressure. Bdph
at this dose did not affect the log dose–response curves of
prazosin and clonidine for changes of systolic pressure in
conscious normotensive rats, suggesting that Bdph at this
dose did not block α1- or activate α2-adrenoceptors. In this
animal model, Bdph at this dose also did not affect the log
Fig. 2 Time course of effects of butylidenephthalide (Bdph) or its vehicle (control) on systolic pressure in conscious normotensive (a) and
spontaneous hypertensive (b) rats. Bdph was injected at 0 min just after the last determination of baseline values. Each point represents mean ±
SEM, and n is the number of rats. There is no significant difference either between test and control (Student’s unpaired t-test), or between before
and after Bdph injection (Student’s paired t-test)
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dose–response curve of Bay K 8644 for changes of systolic
pressure. In contrast, nifedipine (1 mg/kg, i.v.), a reference
drug, significantly reduced the change of systolic pressure
at each dose of Bay K 8644 when compared to its control.
Thus Bdph at this dose did not block Ca2+ channels in con-
scious normotensive rats. However, Bdph at this dose
(30 mg/kg, i.p.) similar to 4-AP (0.4 mg/kg, i.p.) antago-
nized cromakalim-induced decrease of systolic pressure
(Fig. 3a, b). Cromakalim was reported to be an ATP-
sensitive K+ channel opener [21], which may increase out-
flux of K+ and hyperpolarize the membrane of vascular
Fig. 3 Time course of effects of cromakalim on systolic pressure in
conscious normotensive rats, pretreated with butylidenephthalide
(Bdph, a), 4-aminopyridine (4-AP, b), glibenclamide (GBC, c) or their
vehicles (controls). After both second baseline values were determined,
Bdph, 4-AP or GBC was immediately injected at 0 min. Thirty min after
injection of Bdph, 4-AP or GBC, 0.1, 0.15, or 0.3 mg/kg of cromakalim
was injected (i.v.), respectively. Each point represents mean ± SEM, and
n is the number of rats. * P < 0.05, ** P < 0.01, *** P < 0.001 compared
to their respective control
Fig. 4 Effects of butylidenephthalide (Bdph, a), 4-aminopyridine
(4-AP, b) and glibenclamide (GBC, c) on log dose–response curves of
cromakalim for change of systolic pressure in conscious normotensive
rats. All values are shown as mean ± SEM. The number of Bdph-treated
rats was 8, and that of 4-AP- or GBC-treated rats was 6. * P< 0.05,
** P< 0.01 and *** P< 0.001 compared to their respective control
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smooth muscle cells and cause decrease of systolic pres-
sure. In the present results, GBC (10 mg/kg, i.v.), an ATP-
sensitive K+ channel blocker [19], competitively rightward
shifted the log dose–response curve of cromakalim for
changes in systolic pressure. Thus, the antagonistic effect of
Bdph against cromakalim was similar to that of 4-AP, a K+
channel blocker of Kv1 family, and partially similar to that
of GBC, an ATP-sensitive K+ channel blocker. Thus, Bdph
may be a kind of K+ channel blockers, which have been
reviewed to have a potential clinical use for Alzheimer dis-
ease [22]. Indeed, Bdph has also been reported to reverse
the deficits of inhibitory avoidance performance and im-
prove memory in rats [23]. However, further investigation
is needed to determine Bdph how to dock in cromakalim
binding sites.
GBC is one of sulfonylureas, which are powerful oral
hypoglycemic drugs that have been used to treat dia-
betic patients for decades. Since Bdph can antagonize
cromakalim-induced systolic pressure reduction in the
present study, it is not surprising that Bdph was recently
reported to have antihyperglycemic activity in mice [24].
Episodic ataxia type 2 (EA2) is a form of hereditary neuro-
logical disorder caused by cerebellar malfunction and is
characterized by interictal ataxia and frequent attacks of
dyskinesia, vertigo, and imbalance [25]. Recently, 4-AP
was reported to treat EA2 [26, 27]. The target of 4-AP are
Kv1 family of K
+ channels, possibly the Kv1.5 subtype [28].
Further investigation is needed to determine whether
Bdph is useful in treating EA2.
Conclusions
In conclusion, the antagonistic effect of Bdph at the dose
of 30 mg/kg (i.p.) on cromakalim-induced systolic pres-
sure reduction in conscious normotensive rats was simi-
lar to that of 4-AP, a K+ channel blocker of Kv1 family,
and partially similar to that of GBC, a blocker of ATP-
sensitive K+ channels. Thus Bdph may be a kind of K+
channel blockers.
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